Skip to main content
Top
Gepubliceerd in:

11-04-2023

Health-related quality of life and medication use among individuals with Angelman syndrome

Auteurs: Nasreen Khan, Raquel Cabo, Rebecca D. Burdine, Wen-Hann Tan, Christopher J. Keary, Cesar Ochoa-Lubinoff, Lynne M. Bird, On behalf of the STARS Investigators

Gepubliceerd in: Quality of Life Research | Uitgave 7/2023

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

The primary goal of this analysis is to describe the health-related quality of life (HRQoL), medical history, and medication use among adolescents and adults individuals with Angelman syndrome (AS).

Methods

The analysis uses baseline data collected during the STARS study, a double-blind placebo controlled trial of gaboxadol (OV101) in adolescents and adults with AS. The HRQoL was estimated using EuroQoL 5-Dimension 5-Level (EQ-5D) health questionnaire proxy 1 version, which was completed by the caregivers. EQ-5D consists of two parts, a 5-dimension descriptive and a visual analogue scale (VAS) component. The utility score derived from EQ-5D ranges from 0 to 1 (perfect health) and VAS ranges from 0 to 100 (perfect health).

Results

87 individuals with AS were included in the present analysis. The mean utility score was 0.44 ± 0.20 and VAS score was 84 ± 1.5. The EQ-5D data indicated that the self-care, mobility and daily activities were most impacted. All adolescents (100%) and most adults (93%) had at least moderate problems with self-care activities, such as washing or dressing themselves. More than half (55%) of the adolescents and adults had at least moderate issues with mobility and usual activities. Approximately, 30% of adolescents and adults had moderate to extreme problems with anxiety/depression. High baseline concomitant use of medications was observed across both age groups with an average of 5 medications being used per person.

Conclusion

This study highlights the impact of AS on HRQoL and medication utilization among adolescents and adults individuals with AS.
Literatuur
1.
go back to reference Williams, C. A., Beaudet, A. L., Clayton-Smith, J., Knoll, J. H., Kyllerman, M., Laan, L. A., Magenis, R. E., Moncla, A., Schinzel, A. A., Summers, J. A., & Wagstaff, J. (2006). Angelman syndrome 2005: updated consensus for diagnostic criteria. American Journal of Medical Genetics Part A, 140(5), 413–8.CrossRefPubMed Williams, C. A., Beaudet, A. L., Clayton-Smith, J., Knoll, J. H., Kyllerman, M., Laan, L. A., Magenis, R. E., Moncla, A., Schinzel, A. A., Summers, J. A., & Wagstaff, J. (2006). Angelman syndrome 2005: updated consensus for diagnostic criteria. American Journal of Medical Genetics Part A, 140(5), 413–8.CrossRefPubMed
2.
go back to reference Bindels-de Heus, K. G., Mous, S. E., ten Hooven-Radstaake, M., van Iperen-Kolk, B. M., Navis, C., Rietman, A. B., Ten Hoopen, L. W., Brooks, A. S., ENCORE Expertise Center for AS, Elgersma, Y., & Moll, H. A. (2020). An overview of health issues and development in a large clinical cohort of children with Angelman syndrome. American Journal of Medical Genetics Part A, 182(1), 53–63.CrossRefPubMed Bindels-de Heus, K. G., Mous, S. E., ten Hooven-Radstaake, M., van Iperen-Kolk, B. M., Navis, C., Rietman, A. B., Ten Hoopen, L. W., Brooks, A. S., ENCORE Expertise Center for AS, Elgersma, Y., & Moll, H. A. (2020). An overview of health issues and development in a large clinical cohort of children with Angelman syndrome. American Journal of Medical Genetics Part A, 182(1), 53–63.CrossRefPubMed
3.
go back to reference Buiting, K., Williams, C., & Horsthemke, B. (2016). Angelman syndrome - insights into a rare neurogenetic disorder. Nature Reviews. Neurology, 12(10), 584–593.CrossRefPubMed Buiting, K., Williams, C., & Horsthemke, B. (2016). Angelman syndrome - insights into a rare neurogenetic disorder. Nature Reviews. Neurology, 12(10), 584–593.CrossRefPubMed
5.
go back to reference Guerrini, R., Carrozzo, R., Rinaldi, R., & Bonanni, P. (2003). Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms. Paediatric Drugs, 5(10), 647–661.CrossRefPubMed Guerrini, R., Carrozzo, R., Rinaldi, R., & Bonanni, P. (2003). Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms. Paediatric Drugs, 5(10), 647–661.CrossRefPubMed
6.
go back to reference Tan, W. H., & Bird, L. M. (2016). Angelman syndrome: Current and emerging therapies in 2016. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 172(4), 384–401.CrossRefPubMed Tan, W. H., & Bird, L. M. (2016). Angelman syndrome: Current and emerging therapies in 2016. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 172(4), 384–401.CrossRefPubMed
7.
go back to reference Wheeler, A. C., Sacco, P., & Cabo, R. (2017). Unmet clinical needs and burden in Angelman syndrome: A review of the literature. Orphanet Journal of Rare Diseases, 12, 164.CrossRefPubMedPubMedCentral Wheeler, A. C., Sacco, P., & Cabo, R. (2017). Unmet clinical needs and burden in Angelman syndrome: A review of the literature. Orphanet Journal of Rare Diseases, 12, 164.CrossRefPubMedPubMedCentral
8.
go back to reference Khan, N., Cabo, R., Tan, W. H., Tayag, R., & Bird, L. M. (2019). Healthcare burden among individuals with Angelman syndrome: Findings from the Angelman syndrome natural history study. Molecular Genetics & Genomic Medicine, 7(7), e00734.CrossRef Khan, N., Cabo, R., Tan, W. H., Tayag, R., & Bird, L. M. (2019). Healthcare burden among individuals with Angelman syndrome: Findings from the Angelman syndrome natural history study. Molecular Genetics & Genomic Medicine, 7(7), e00734.CrossRef
9.
go back to reference Griffith, G. M., Hastings, R. P., Oliver, C., Howlin, P., Moss, J., Petty, J., & Tunnicliffe, P. (2011). Psychological well-being in parents of children with Angelman, Cornelia de Lange and Cri du Chat syndromes. Journal of Intellectual Disability Research, 55(4), 397–410.CrossRefPubMed Griffith, G. M., Hastings, R. P., Oliver, C., Howlin, P., Moss, J., Petty, J., & Tunnicliffe, P. (2011). Psychological well-being in parents of children with Angelman, Cornelia de Lange and Cri du Chat syndromes. Journal of Intellectual Disability Research, 55(4), 397–410.CrossRefPubMed
10.
go back to reference Willgoss, T., Cassater, D., Connor, S., Krishnan, M. L., Miller, M. T., Dias-Barbosa, C., Phillips, D., McCormack, J., Bird, L. M., Burdine, R. D., & Claridge, S. (2021). Measuring what matters to individuals with Angelman syndrome and their families: development of a patient-centered disease concept model. Child Psychiatry & Human Development. https://doi.org/10.1007/s10578-020-01051-zCrossRef Willgoss, T., Cassater, D., Connor, S., Krishnan, M. L., Miller, M. T., Dias-Barbosa, C., Phillips, D., McCormack, J., Bird, L. M., Burdine, R. D., & Claridge, S. (2021). Measuring what matters to individuals with Angelman syndrome and their families: development of a patient-centered disease concept model. Child Psychiatry & Human Development. https://​doi.​org/​10.​1007/​s10578-020-01051-zCrossRef
11.
go back to reference Larson, A. M., Shinnick, J. E., Shaaya, E. A., Thiele, E. A., & Thibert, R. L. (2015). Angelman syndrome in adulthood. American Journal of Medical Genetics Part A, 167A(2), 331–344.CrossRefPubMed Larson, A. M., Shinnick, J. E., Shaaya, E. A., Thiele, E. A., & Thibert, R. L. (2015). Angelman syndrome in adulthood. American Journal of Medical Genetics Part A, 167A(2), 331–344.CrossRefPubMed
12.
go back to reference Adams, D., Clarke, S., Griffith, G., Howlin, P., Moss, J., Petty, J., Tunnicliffe, P., & Oliver, C. (2018). Mental health and well-being in mothers of children with rare genetic syndromes showing chronic challenging behavior: A cross-sectional and longitudinal study. American Journal on Intellectual and Developmental Disabilities, 123(3), 241–253.CrossRefPubMed Adams, D., Clarke, S., Griffith, G., Howlin, P., Moss, J., Petty, J., Tunnicliffe, P., & Oliver, C. (2018). Mental health and well-being in mothers of children with rare genetic syndromes showing chronic challenging behavior: A cross-sectional and longitudinal study. American Journal on Intellectual and Developmental Disabilities, 123(3), 241–253.CrossRefPubMed
13.
go back to reference Grieco, J. C., Romero, B., Flood, E., Cabo, R., & Visootsak, J. (2019). Conceptual model of Angelman syndrome and review of relevant clinical outcomes assessments (COAs). Patient, 12(1), 97–112.CrossRefPubMed Grieco, J. C., Romero, B., Flood, E., Cabo, R., & Visootsak, J. (2019). Conceptual model of Angelman syndrome and review of relevant clinical outcomes assessments (COAs). Patient, 12(1), 97–112.CrossRefPubMed
14.
go back to reference Khan, N., Cabo, R., Tan, W. H., Tayag, R., & Bird, L. M. (2019). An observational study of pediatric healthcare burden in Angelman syndrome: results from a real-world study. Orphanet Journal of Rare Diseases, 14, 239.CrossRefPubMedPubMedCentral Khan, N., Cabo, R., Tan, W. H., Tayag, R., & Bird, L. M. (2019). An observational study of pediatric healthcare burden in Angelman syndrome: results from a real-world study. Orphanet Journal of Rare Diseases, 14, 239.CrossRefPubMedPubMedCentral
15.
go back to reference Thomson, A. K., Glasson, E. J., & Bittles, A. H. (2006). A long-term population-based clinical and morbidity profile of Angelman syndrome in Western Australia: 1953–2003. Disability and Rehabilitation, 28(5), 299–305.CrossRefPubMed Thomson, A. K., Glasson, E. J., & Bittles, A. H. (2006). A long-term population-based clinical and morbidity profile of Angelman syndrome in Western Australia: 1953–2003. Disability and Rehabilitation, 28(5), 299–305.CrossRefPubMed
16.
go back to reference Domínguez-Berjón, M. F., Zoni, A. C., Esteban-Vasallo, M. D., Sendra-Gutiérrez, J. M., & Astray-Mochales, J. (2018). Main causes of hospitalization in people with Angelman syndrome. Journal of Applied Research in Intellectual Disabilities, 31(3), 466–469.CrossRefPubMed Domínguez-Berjón, M. F., Zoni, A. C., Esteban-Vasallo, M. D., Sendra-Gutiérrez, J. M., & Astray-Mochales, J. (2018). Main causes of hospitalization in people with Angelman syndrome. Journal of Applied Research in Intellectual Disabilities, 31(3), 466–469.CrossRefPubMed
18.
go back to reference Herdman, M., Gudex, C., Lloyd, A., Janssen, M. F., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–36.CrossRefPubMedPubMedCentral Herdman, M., Gudex, C., Lloyd, A., Janssen, M. F., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–36.CrossRefPubMedPubMedCentral
19.
go back to reference Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.CrossRefPubMed Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.CrossRefPubMed
20.
go back to reference Pickard, A. S., Law, E. H., Jiang, R., Pullenayegum, E., Shaw, J. W., Xie, F., Oppe, M., Boye, K. S., Chapman, R. H., Gong, C. L., & Balch, A. (2019). United States valuation of EQ-5D-5L health states using an international protocol. Value in Health, 22(8), 931–941.CrossRefPubMed Pickard, A. S., Law, E. H., Jiang, R., Pullenayegum, E., Shaw, J. W., Xie, F., Oppe, M., Boye, K. S., Chapman, R. H., Gong, C. L., & Balch, A. (2019). United States valuation of EQ-5D-5L health states using an international protocol. Value in Health, 22(8), 931–941.CrossRefPubMed
21.
go back to reference Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. Medical Care, 43(3), 203–220.CrossRefPubMed Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. Medical Care, 43(3), 203–220.CrossRefPubMed
22.
go back to reference Euroquol, G. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef Euroquol, G. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef
23.
go back to reference Janssen, B., & Szende, A. (2014). Population Norms for the EQ-5D. Self-Reported Population Health: An International Perspective based on EQ-5D, in Self-Reported Population Health: An International Perspective based on EQ-5D. Springer. Janssen, B., & Szende, A. (2014). Population Norms for the EQ-5D. Self-Reported Population Health: An International Perspective based on EQ-5D, in Self-Reported Population Health: An International Perspective based on EQ-5D. Springer.
24.
go back to reference Jiang, R., Janssen, M. F. B., & Pickard, A. S. (2021). US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Quality of Life Research, 30(3), 803–816.CrossRefPubMed Jiang, R., Janssen, M. F. B., & Pickard, A. S. (2021). US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Quality of Life Research, 30(3), 803–816.CrossRefPubMed
25.
go back to reference Chevreul, K., Gandré, C., Brigham, K. B., López-Bastida, J., Linertová, R., Oliva-Moreno, J., Serrano-Aguilar, P., Posada-de-la-Paz, M., Taruscio, D., Schieppati, A., & Iskrov, G. (2016). Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe. The European Journal of Health Economics, 17(Suppl 1), 43–52.CrossRefPubMed Chevreul, K., Gandré, C., Brigham, K. B., López-Bastida, J., Linertová, R., Oliva-Moreno, J., Serrano-Aguilar, P., Posada-de-la-Paz, M., Taruscio, D., Schieppati, A., & Iskrov, G. (2016). Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe. The European Journal of Health Economics, 17(Suppl 1), 43–52.CrossRefPubMed
26.
go back to reference Cavazza, M., et al. (2016). Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. The European Journal of Health Economics, 17(Suppl 1), 19–29.CrossRefPubMed Cavazza, M., et al. (2016). Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. The European Journal of Health Economics, 17(Suppl 1), 19–29.CrossRefPubMed
27.
go back to reference Lin, J., Wong, C. K. H., Cheung, J. P. Y., Cheung, P. W. H., & Luo, N. (2022). Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis. The European Journal of Health Economics, 23(8), 1383–95.CrossRefPubMed Lin, J., Wong, C. K. H., Cheung, J. P. Y., Cheung, P. W. H., & Luo, N. (2022). Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis. The European Journal of Health Economics, 23(8), 1383–95.CrossRefPubMed
28.
go back to reference Takura, T., Koike, T., Matsuo, Y., Sekimoto, A., & Mutou, M. (2022). Proxy responses regarding quality of life of patients with terminal lung cancer: preliminary results from a prospective observational study. BMJ Open, 12(2), e048232.CrossRefPubMedPubMedCentral Takura, T., Koike, T., Matsuo, Y., Sekimoto, A., & Mutou, M. (2022). Proxy responses regarding quality of life of patients with terminal lung cancer: preliminary results from a prospective observational study. BMJ Open, 12(2), e048232.CrossRefPubMedPubMedCentral
29.
go back to reference Kelly, C., Hulme, C., Graham, L., Ellwood, A., Patel, I., Cundill, B., Farrin, A., Goodwin, M., Hull, K., Fisher, J., & Forster, A. (2021). Inter-rater reliability of care home staff’s proxy judgements with residents’ assessments of their own health-related quality of life: an analysis of the PATCH trial EQ-5D data. Age Ageing, 50(4), 1314–1320.CrossRefPubMedPubMedCentral Kelly, C., Hulme, C., Graham, L., Ellwood, A., Patel, I., Cundill, B., Farrin, A., Goodwin, M., Hull, K., Fisher, J., & Forster, A. (2021). Inter-rater reliability of care home staff’s proxy judgements with residents’ assessments of their own health-related quality of life: an analysis of the PATCH trial EQ-5D data. Age Ageing, 50(4), 1314–1320.CrossRefPubMedPubMedCentral
30.
go back to reference Fitriana, T. S., Purba, F. D., Stolk, E., & Busschbach, J. J. (2022). EQ-5D-Y-3L and EQ-5D-Y-5L proxy report: psychometric performance and agreement with self-report. Health and Quality of Life Outcomes, 20(1), 88.CrossRefPubMedPubMedCentral Fitriana, T. S., Purba, F. D., Stolk, E., & Busschbach, J. J. (2022). EQ-5D-Y-3L and EQ-5D-Y-5L proxy report: psychometric performance and agreement with self-report. Health and Quality of Life Outcomes, 20(1), 88.CrossRefPubMedPubMedCentral
31.
go back to reference Balboni, G., Coscarelli, A., Giunti, G., & Schalock, R. L. (2013). The assessment of the quality of life of adults with intellectual disability: The use of self-report and report of others assessment strategies. Research in Developmental Disabilities., 34(11), 4248–4254.CrossRefPubMed Balboni, G., Coscarelli, A., Giunti, G., & Schalock, R. L. (2013). The assessment of the quality of life of adults with intellectual disability: The use of self-report and report of others assessment strategies. Research in Developmental Disabilities., 34(11), 4248–4254.CrossRefPubMed
32.
go back to reference Lamsal, R., Finlay, B., Whitehurst, D. G., & Zwicker, J. D. (2020). Generic preference-based health-related quality of life in children with neurodevelopmental disorders: a scoping review. Developmental Medicine & Child Neurology, 62(2), 169–177.CrossRef Lamsal, R., Finlay, B., Whitehurst, D. G., & Zwicker, J. D. (2020). Generic preference-based health-related quality of life in children with neurodevelopmental disorders: a scoping review. Developmental Medicine & Child Neurology, 62(2), 169–177.CrossRef
33.
go back to reference Péntek, M., Gulácsi, L., Brodszky, V., Baji, P., Boncz, I., Pogány, G., López-Bastida, J., Linertová, R., Oliva-Moreno, J., Serrano-Aguilar, P., & Posada-de-la-Paz, M. (2016). Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. The European Journal of Health Economics, 17(Suppl 1), 89–98.CrossRefPubMed Péntek, M., Gulácsi, L., Brodszky, V., Baji, P., Boncz, I., Pogány, G., López-Bastida, J., Linertová, R., Oliva-Moreno, J., Serrano-Aguilar, P., & Posada-de-la-Paz, M. (2016). Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. The European Journal of Health Economics, 17(Suppl 1), 89–98.CrossRefPubMed
34.
go back to reference López-Bastida, J., Linertová, R., Oliva-Moreno, J., Posada-de-la-Paz, M., Serrano-Aguilar, P., Kanavos, P., Taruscio, D., Schieppati, A., Iskrov, G., Baji, P., & Delgado, C. (2016). Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe. The European Journal of Health Economics, 17(Suppl 1), 99–108.CrossRefPubMed López-Bastida, J., Linertová, R., Oliva-Moreno, J., Posada-de-la-Paz, M., Serrano-Aguilar, P., Kanavos, P., Taruscio, D., Schieppati, A., Iskrov, G., Baji, P., & Delgado, C. (2016). Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe. The European Journal of Health Economics, 17(Suppl 1), 99–108.CrossRefPubMed
Metagegevens
Titel
Health-related quality of life and medication use among individuals with Angelman syndrome
Auteurs
Nasreen Khan
Raquel Cabo
Rebecca D. Burdine
Wen-Hann Tan
Christopher J. Keary
Cesar Ochoa-Lubinoff
Lynne M. Bird
On behalf of the STARS Investigators
Publicatiedatum
11-04-2023
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 7/2023
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-023-03375-4

Andere artikelen Uitgave 7/2023

Quality of Life Research 7/2023 Naar de uitgave